Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel + oxaliplatin + S-1 for large type 3 or type 4 gastric cancer
jRCTs051190060Phase 2Completed
- Sponsor
- Yakult Honsha
- Start
- Oct 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin and tegafur in gastric cancer (GC), sponsored by Yakult Honsha. Primary endpoint: 3-year progression-free survival rate. Started Oct 2019; status: completed.
02
Drugs
docetaxeloxaliplatintegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs051190060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190060.